Program
zovegalisib
Its studies are mostly in Lymphatic Abnormalities · Breast Neoplasms, led by Relay Therapeutics.
Furthest: phase 2, since Jan 17, 20252 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Relay Therapeutics | 22 open or running | phase 2since Jan 17, 2025 | Dec 20, 2021 | Apr 30, 2027phase 1 · NCT05216432 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2021First study: phase 1 study in Breast NeoplasmsFirst studyNCT05216432 · 930 planned · United States, Australia, France and more
- Jan 17, 2025Phase 2 study in Lymphatic AbnormalitiesNCT06789913 · 277 planned · United States, Australia, Belgium and more
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT05216432
- Jul 2031Primary completion: phase 2 study in Lymphatic AbnormalitiesNCT06789913
TargetBeta
PIK3CA →read by rule
“An orally bioavailable, pan-mutant selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (phosphoinositide 3-kinase alpha; PIK3CA; PI3K p110alpha), ”NCIt, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alpelisibrule | Novartis | phase 4 | 37 |
| inavolisibrule | Hoffmann-La Roche | phase 3 | 20 |
| tersolisib | Eli Lilly | phase 3 | 10 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| serabelisibrule | Takeda | phase 2 | 11 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| risovalisibrule | Haihe Biopharma | phase 2 | 4 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | ensem-therapeutics | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06789913Lymphatic Abnormalities · United States, Australia, Belgium and more | 2 | Recruiting | Jul 2031 | 277 |
| NCT05216432Breast Neoplasms · United States, Australia, France and more | 1 | Recruiting | Apr 30, 2027 | 930 |
How it is read
Names in the registry
- “RLY-2608”, 2 entries
Conditions, from the studies’ own filings
- Lymphatic Abnormalities, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.